Literature DB >> 24756568

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.

Elodie Nerrant1, Céline Salsac2, Mahmoud Charif1, Xavier Ayrignac1, Clarisse Carra-Dalliere1, Giovanni Castelnovo3, Radjiv Goulabchand1, Julie Tisseyre4, Cédric Raoul2, Jean-François Eliaou4, Pierre Labauge1, Thierry Vincent5.   

Abstract

BACKGROUND: auto-antibodies against the potassium channel inward rectifying potassium channel 4.1 (Kir4.1) have previously been identified in 46% of patients with multiple sclerosis (MS).
OBJECTIVES: to confirm these findings.
METHODS: we evaluated the presence of anti-Kir4.1 antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence in 268 MS patients, 46 patients with other neurological diseases (OND) and 45 healthy controls.
RESULTS: anti-Kir4.1 antibodies were found in 7.5% of MS patients, 4.3% of OND patients and 4.4% of healthy controls. Immunofluorescence analysis did not identify any specific staining.
CONCLUSIONS: we confirmed the presence of anti-Kir4.1 antibodies in MS patients, but at a much lower prevalence than previously reported.
© The Author(s), 2014.

Entities:  

Keywords:  ELISA; Kir4.1 antibody; Multiple sclerosis; biomarker; diagnosis

Mesh:

Substances:

Year:  2014        PMID: 24756568     DOI: 10.1177/1352458514531086

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  22 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  Some recent advances in multiple sclerosis.

Authors:  Claire McCarthy; John Thorpe
Journal:  J Neurol       Date:  2016-04-25       Impact factor: 4.849

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 5.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 6.  The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Authors:  Rui Li; Amit Bar-Or
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 7.  The role of glial-specific Kir4.1 in normal and pathological states of the CNS.

Authors:  Sinifunanya E Nwaobi; Vishnu A Cuddapah; Kelsey C Patterson; Anita C Randolph; Michelle L Olsen
Journal:  Acta Neuropathol       Date:  2016-03-09       Impact factor: 17.088

Review 8.  CD19 as a molecular target in CNS autoimmunity.

Authors:  Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz
Journal:  Acta Neuropathol       Date:  2014-07-04       Impact factor: 17.088

9.  Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

Authors:  Adipong Brickshawana; Shannon R Hinson; Michael F Romero; Claudia F Lucchinetti; Yong Guo; Mathias Buttmann; Andrew McKeon; Sean J Pittock; Min-Hwang Chang; An-Ping Chen; Thomas J Kryzer; James P Fryer; Sarah M Jenkins; Philippe Cabre; Vanda A Lennon
Journal:  Lancet Neurol       Date:  2014-07-06       Impact factor: 44.182

Review 10.  New autoantibody detection technologies yield novel insights into autoimmune disease.

Authors:  Peter D Burbelo; Terrance P O'Hanlon
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.